Highest-materiality recent filing
39% of 25 mg arm achieved ≥25% MADRS reduction at Week 6, maintained through Week 26.
Q1 net income $91.2M on warrant gain; cash $466M; FDA grants COMP360 rolling NDA submission
FDA granted Compass NDA rolling submission for COMP360 in TRD based on positive Phase 3 data; CNPV awarded.
Compass Pathways 2025 net loss $287.9M; COMP360 NDA submission on track for Q4 2026
Full-year 2025 net loss $287.9M ($3.08/share), vs $155.1M in 2024; includes $122.6M non-cash loss on warrant liabilities.
Compass Pathways prices $150M public offering of ADSs and pre-funded warrants
Gross proceeds $150M from 17.5M ADSs at $8/ADS and 1.25M pre-funded warrants at $7.9999 each.
COMP006: Two 25mg doses vs 1mg showed -3.8 point MADRS reduction (p<0.001) at Week 6, meeting primary endpoint.
COMPASS Pathways secures $150M loan from Hercules Capital, $50M funded immediately
New $150M term loan facility with Hercules Capital; $50M drawn on Jan 5, 2026 (Tranche 1).
Compass Pathways accelerates COMP360 TRD launch by 9-12 months; Q3 net loss $137.7M
Accelerating commercialization readiness by 9-12 months after positive FDA meeting on NDA strategy including potential rolling submission.
Compass Pathways reports Q2 2025 net loss $38.4M; COMP360 Phase 3 trial hits primary endpoint
Positive Phase 3 COMP005 trial: primary endpoint met with high statistical significance and clinically meaningful reduction in depression symptoms at 6 weeks for COMP360 in TRD.
Compass Pathways positive Phase 3 COMP005 psilocybin trial meets primary endpoint for TRD
COMP360 25 mg single dose showed MADRS reduction -3.6 vs placebo (p<0.001) at week 6.
Compass Pathways Q1 net loss $17.9M; cash $260.1M; phase 3 top-line data expected late June
Net loss $17.9M ($0.24 diluted EPS) vs $35.2M ($0.55) in Q1 2024; includes $19.5M non-cash gain on warrant liabilities.
Compass Pathways reports FY2024 net loss of $155.1M; Phase 3 data on track for Q2 2025
Net loss for FY2024 was $155.1M ($2.30 loss per share) vs $118.5M ($2.32 loss per share) in FY2023.
Compass Pathways prices $150M offering of ADS and warrants to fund Phase 3 depression/PTSD trials
Offering of 24.0M ADS and 11.0M pre-funded warrants plus accompanying ADS warrants at $4.275/unit (ADS warrant strike $5.796).
Compass Pathways delays COMP360 phase 3 data to Q2 2025; workforce reduction of 30%
COMP005 phase 3 top-line data in TRD now expected Q2 2025; COMP006 data shifted to H2 2026 after unblinding risk.
Compass Pathways Q2 net loss $38.1M; COMP005 phase 3 TRD data expected Q4 2024
Net loss of $38.1M ($0.56 per share) vs $28.3M in Q2 2023; R&D expenses rose to $29.1M.
Compass Pathways Q1 net loss $35.2M ($0.55/share); phase 3 TRD on track; PTSD phase 2 positive
Net loss $35.2M vs $24.2M in Q1 2023; EPS loss $0.55 vs $0.57.
Compass Pathways reports positive Ph2 data for COMP360 psilocybin in PTSD; meets safety endpoint
Phase 2 open-label study of 22 PTSD patients; single 25mg dose plus psychological support met primary safety endpoint.
Resignations effective March 29, 2024; not due to any disagreement with company.
Compass Pathways Q4 2023 net loss $32.5M; COMP005 data delayed to Q4 2024
Net loss for FY2023 $118.5M ($2.32/sh) vs $91.5M ($2.16/sh) in 2022.
COMPASS Pathways Q3 net loss $33.4M; COMP360 Phase 3 on track; cash $248M
Net loss $33.4M ($0.67/share) for Q3 2023 vs $18.4M ($0.43) YoY; R&D expenses rose to $21.5M.
COMPASS Pathways CFO Mike Falvey departs; Mary-Rose Hughes named interim CFO
CFO Michael Falvey resigns effective Oct 26; will advise through Nov 3 to pursue other opportunities.
COMPASS Pathways raises $125M upfront in private placement; warrants could add $160M
Issued 16.08M ADSs and warrants to purchase 16.08M ADSs at $7.78 per unit; warrant strike $9.93 (30% premium).
COMPASS Pathways H1 2023 net loss $52.5M; Phase 3 psilocybin trials on track
Net loss for H1 2023: $52.5M ($1.19 loss per share) vs $42.2M ($1.00) in H1 2022.
Compass Pathways secures up to $50M term loan from Hercules Capital, draws $30M initially
Loan facility up to $50M; initial $30M drawn on June 30, 2023; two additional tranches of $10M each available subject to milestones and lender approval.
COMPASS Pathways Q1 net loss $24.2M ($0.57/sh); Phase 3 psilocybin trials underway
Net loss $24.2M ($0.57 loss per share) vs $21.2M ($0.50) in Q1 2022.
COMPASS Pathways reports FY2022 net loss of $91.5M; Phase 3 psilocybin trials underway
Net loss for FY2022 was $91.5M ($2.16 loss per share) vs $71.7M ($1.79 loss per share) in 2021.
COMPASS Pathways reports Q2 net loss of $21.0M, appoints Kabir Nath as CEO
Net loss for Q2 2022 was $21.0M ($0.50 loss per share) vs $17.5M ($0.44) in Q2 2021.
Kabir Nath appointed CEO, effective August 1, 2022; he brings 30 years biopharma experience, most recently at Otsuka and Bristol-Myers Squibb.
PTAB denies post-grant review of two Compass Pathways patents
Patent Trial & Appeal Board denied institution of post-grant review for US patents 10,947,257 and 10,954,259 on June 22, 2022.
Up to £12M investment over 10-year term; Centre to accelerate psychedelic therapy research and new care models.
Net loss for FY2021 was $71.7M ($1.79 loss per share), vs $60.3M in FY2020; Q4 net loss $25.7M.
On July 30, 2024, the board of directors (the “Board”) of the Company appointed Gino Santini to join the Board and to serve as Chairman, effective September 3 , 2024, and designated him as a Class I director.
On March 27, 2024, George Goldsmith and Ekaterina Malievskaia submitted their resignations from the board of directors (the " Board ") of COMPASS Pathways plc (the “ Company ”) with an effective date of March 29, 2024.
On March 27, 2024, George Goldsmith and Ekaterina Malievskaia submitted their resignations from the board of directors (the " Board ") of COMPASS Pathways plc (the “ Company ”) with an effective date of March 29, 2024.
David Norton, who currently serves as lead independent director, will assume the role of Chair of the Board.
appointed Teri Loxam as chief financial officer, principal financial officer and principal accounting officer, effective as of the later of March 1, 2024 or the filing of the Company’s annual report for the period ending December 31, 2023 (the “Effective Date”).
Michael Falvey, Chief Financial Officer, principal financial officer and principal accounting officer of COMPASS Pathways plc (the “Company”), resigned from his role as chief financial officer to pursue other opportunities effective October 26, 2023.
Effective October 26, 2023, the Company appointed Mary-Rose Hughes as its Interim Chief Financial Officer until such time as the Company appoints a new chief financial officer.
On September 13, 2023, the board of directors (the “Board”) of COMPASS Pathways plc (the “Company”), upon the recommendation of its nominating and corporate governance committee, appointed Daphne Karydas to join the Board, effective September 1 8, 2023, and designated her as a Class III director.
Dr. Malievskaia will step down from her executive role and that her employment agreement will terminate effective June 16, 2023
On July 19, 2022, COMPASS Pathways plc (the “Company”) announced that its board of directors has appointed Kabir Nath as the Company’s chief executive officer effective August 1, 2022.
Mr. Nath will also be appointed as a member of the board of directors as a Class II director effective as of August 1, 2022.
On April 19, 2022, Jason Camm notified COMPASS Pathways plc (the “Company”) of his intent not to stand for re-election as a director of the Company at the Company’s 2022 annual general meeting of shareholders due to be held on or around June 16, 2022 (the “Annual Meeting”).
Max materiality 0.90 · Median 0.65 · Most common event earnings